Aethlon Medical Past Earnings Performance

Past criteria checks 0/6

Aethlon Medical's earnings have been declining at an average annual rate of -14.9%, while the Medical Equipment industry saw earnings declining at 2.5% annually. Revenues have been declining at an average rate of 21.6% per year.

Key information

-14.9%

Earnings growth rate

50.6%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate-21.6%
Return on equity-187.2%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Aethlon Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:EJU0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-11110
30 Jun 240-11110
31 Mar 240-12120
31 Dec 231-12120
30 Sep 231-12120
30 Jun 231-12130
31 Mar 231-12120
31 Dec 220-13130
30 Sep 220-13130
30 Jun 220-11110
31 Mar 220-10110
31 Dec 210-990
30 Sep 211-9100
30 Jun 211-990
31 Mar 211-890
31 Dec 201-780
30 Sep 201-660
30 Jun 201-660
31 Mar 201-670
31 Dec 191-660
30 Sep 190-770
30 Jun 190-770
31 Mar 190-660
31 Dec 180-660
30 Sep 180-550
30 Jun 180-550
31 Mar 180-650
31 Dec 170-650
30 Sep 170-650
30 Jun 170-770
31 Mar 170-760
31 Dec 161-760
30 Sep 161-760
30 Jun 161-650
31 Mar 161-550
31 Dec 151-550
30 Sep 151-550
30 Jun 151-450
31 Mar 151-750
31 Dec 141-1350
30 Sep 141-1450
30 Jun 141-1750
31 Mar 142-1350

Quality Earnings: EJU0 is currently unprofitable.

Growing Profit Margin: EJU0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EJU0 is unprofitable, and losses have increased over the past 5 years at a rate of 14.9% per year.

Accelerating Growth: Unable to compare EJU0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EJU0 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: EJU0 has a negative Return on Equity (-187.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 19:45
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aethlon Medical, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vernon BernardinoH.C. Wainwright & Co.
Anthony VendettiMaxim Group
Ajay TandonSeeThruEquity, LLC